RANI Stock Forecast & Price Target

Rani Therapeutics Hldgs is a clinical-stage biotherapeutics company with a promising technology, the RaniPill capsule, which aims to improve the patient experience by delivering biologic drugs orally. The company's pipeline includes multiple preclinical and clinical programs targeting obesity, psoriasis, osteoporosis, and psoriatic arthritis, with a strong focus on biosimilar and dual-agonist formulations. While there is always the risk of clinical trial failure and management turnover, Rani is well capitalized with a cash runway through 2028 and a potential for strong data in the future, making it an attractive investment opportunity.

Rani Therapeutics Hldgs is a promising clinical-stage biotherapeutics company with a strong potential to tap into the huge market for obesity treatment through its innovative RaniPill capsule. However, with the Phase 1 clinical trial for RT-114 expected to report data in 2H26, investors may have to wait longer to see the full potential of the drug and its differentiated profile. Additionally, the company's decreasing operating expenses may not fully offset the potential dilution from its October 2025 capital raise, resulting in a reduced price target. As such, it is important for the company to continue advancing its pipeline and establishing strategic partnerships to mitigate risks and maintain investor confidence.